Anne van Rongen
- Name
- Dr. A. van Rongen
Postdoc at Quantative Clinical Pharmacology.
- Lau C., Kesteren C. van, Smeenk R.M., Beex‐Oosterhuis M.M., Koch B.C.P., Chan L.‐N., Lin Y.S., Rongen A., Knibbe C.A.J., Huitema A.D.R. & Huisman‐Siebinga H. (2026), Semi‐physiological population pharmacokinetic modeling of oral and intravenous paracetamol to quantify presystemic metabolism and enterohepatic recirculation, CPT: Pharmacometrics & Systems Pharmacology 15(3): 1-14 (e70168).
- Rongen A. van, Grijseels R., Calvier E.A.M., Allegaert K., Knibbe C.A.J. & Krekels E.H.J. (2025), Changes in the fraction metabolized in children younger than four years: when is clearance scaling for the dominant elimination route in adults appropriate?, Pharmaceutical Research 42: 1691-1700.
- Wu Y., Völler S., Goulooze S.C., Allegaert K., Sherwin C.M.T., Rongen A. van, Roofthooft D.W.E., Simons S.H.P., Tibboel D., Flint R.B., Anker J.N. van den & Knibbe C.A.J. (2025), A novel maturation equation for hepatic clearance across preterm, term neonates, children, and adults: application to paracetamol and its metabolite, The Journal of Clinical Pharmacology 65(12): 1829-1843.
- Rongen A. van, Krekels E.H.J., Calvier E.A.M., Wildt S.N. de, Vermeulen A. & Knibbe C.A.J. (2022), An update on the use of allometric and other scaling methods to scale drug clearance in children: towards decision tables, Expert Opinion on Drug Metabolism & Toxicology 18(2): 99-113.
- Rongen A. van, Anker J.N. van den & Knibbe C.A.J. (2018), Author's Reply to Reith: "Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults", Clinical Pharmacokinetics 57(10): 1357-1358.
- Rongen A. van, Valitalo P.A.J. & Knibbe C.A.J. (2018), Author's Reply to Reith: "Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen", Clinical Pharmacokinetics 57(7): 897-899.
- Rongen A. van, Aa M.P van der, Matic M., Schaik R.H.N. van, Deneer V.H.M., Vorst M.M. van der & Knibbe C.A.J. (2018), Increased Metformin Clearance in Overweight and Obese Adolescents: A Pharmacokinetic Substudy of a Randomized Controlled Trial, Pediatric Drugs 20(4): 365-374.
- Rongen A. van, Brill M.J.E., Vaughns J.D., Välitalo P.A.J., Dongen E.P.A. van, Ramshorst B. van, Barrett J.S., Anker J.N. van den & Knibbe C.A.J. (2017), Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults, Clinical Pharmacokinetics 57(5): 601-611.
- Lempers V.J., Rongen A. van, Dongen E.P. van, Ramshorst B. van, Burger D.M., Aarnoutse R.E., Knibbe C.A.J. & Bruggemann R.J. (2016), Does weight impact anidulafungin pharmacokinetics?, Clinical Pharmacokinetics 55(10): 1289-1294.
- Rongen A. van, Välitalo P.A.J., Peeters M.Y., Boerma D., Huisman F.W., Ramshorst B. van, Dongen E.P. van, Anker J.N. van den & Knibbe C.A.J. (2016), Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen, Clinical Pharmacokinetics 55(7): 833-847.
- Rongen A. van (7 December 2016), The impact of obesity on the pharmacokinetics of drugs in adolescents and adults (Dissertatie. Leiden Academic Center for Drug Research (LACDR), Science, Leiden University). Supervisor(s) and Co-supervisor(s): Knibbe C.A.J. & Anker J.N. van den, Dongen H.P.A. van & Ramshorst B. van.
- Brill M.J., Rongen A. van, Houwink A.P., Burggraaf J., Ramshorst B. van, Wiezer R.J., Dongen E.P. van & Knibbe C.A. (2014), Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers, Clinical Pharmacokinetics 53(10): 931-941.